Effective therapy for acute antibody-mediated rejection with mild chronic changes: case report and review of the literature.

To reduce the long-term toxicities of immunosuppressant drugs, corticosteroid-sparing and calcineurin-inhibitor-sparing immunosuppression protocols have become increasingly popular in managing kidney transplant recipients. The most vexing clinical condition caused by antibodies in organ transplants is antibody-mediated rejection. Limitations of the current antibody-mediated rejection therapies include (1) antibody-mediated rejection reversal tends to be gradual rather than prompt, (2) expense, (3) rejection reversal rates below 80%, (4) common appearance of chronic rejection after antibody-mediated rejection treatment, and (5) long-term persistence of donor specific antibodies after therapy. Because these limitations may be due to a lack of effects on mature plasma cells, the effects of bortezomib on mature plasma cells may represent a quantum advance in antihumoral therapy. Our experiences represent the first clinical use of bortezomib as an antihumoral agent in renal allograft recipients in Kuwait. We present 2 cases with resistant-acute antibody-mediated rejection to the standard therapies that were managed successfully with bortezomib.

[1]  I. Helal,et al.  Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation. , 2011, Transplantation proceedings.

[2]  T. Srinivas,et al.  The Role of Proteasome Inhibition With Bortezomib in the Treatment of Antibody-Mediated Rejection After Kidney-Only or Kidney-Combined Organ Transplantation , 2010, Transplantation.

[3]  C. Ponticelli,et al.  Calcineurin Inhibitors in Renal Transplantation Still Needed but in Reduced Doses: A Review , 2010 .

[4]  T. Pruett.  Abrogation of Anti-HLA Antibodies via Proteasome Inhibition , 2010 .

[5]  B. Tönshoff,et al.  Treatment Strategies to Minimize or Prevent Chronic Allograft Dysfunction in Pediatric Renal Transplant Recipients , 2009, Paediatric drugs.

[6]  J. Platt,et al.  The role of antibodies in transplantation. , 2009, Transplantation reviews.

[7]  D. Cantarovich,et al.  Minimization protocols in pancreas transplantation , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[8]  R. Alloway,et al.  Proteasome inhibition reduces donor-specific antibody levels. , 2009, Transplantation proceedings.

[9]  R. Alloway,et al.  Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection , 2008, Transplantation.

[10]  R. Kyle,et al.  Multiple myeloma. , 2008, Blood.

[11]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[12]  P. Nickerson,et al.  National Conference to Assess Antibody‐Mediated Rejection in Solid Organ Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  N. Fineberg,et al.  Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1 , 2004, Transplantation.

[14]  R. Colvin,et al.  Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment , 2002, Current opinion in nephrology and hypertension.

[15]  J. Platt,et al.  PLATELET-MEDIATED ACTIVATION OF ENDOTHELIAL CELLS: IMPLICATIONS FOR THE PATHOGENESIS OF TRANSPLANT REJECTION1 , 2001, Transplantation.

[16]  W. Duguid,et al.  Role of proteasomes in T cell activation and proliferation. , 1998, Journal of immunology.